Welcome to IJSDR UGC CARE norms ugc approved journal norms IJRTI Research Journal | ISSN : 2455-2631
International Peer Reviewed & Refereed Journals, Open Access Journal
ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.15 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)

Issue: March 2023

Volume 8 | Issue 3

Impact factor: 8.15

Click Here For more Info

Imp Links for Author
Imp Links for Reviewer
Research Area
Subscribe IJSDR
Visitor Counter

Copyright Infringement Claims
Indexing Partner
Published Paper Details
Paper Title: A Comprehensive Review on Ivacaftor
Authors Name: Radheshyam Sonar , Rutwik Talokar , Ved Yawalikar, , Aditya Ubhale
Unique Id: IJSDR2212057
Published In: Volume 7 Issue 12, December-2022
Abstract: Cystic fibrosis (CF) is multisystemic disorder presenting in new born period to adulthood, predominantly affecting respiratory system. It is caused by mutation in CF transmembrane conductance regulator gene. ∆F508 is the most common mutation seen worldwide. Supportive management with bronchodilators, anti-inflammatory, mucolytics, antibiotics are the corner stone of therapy. Mutation specific drug, Ivacaftor, was recently approved USFDA in January 2012 for patients carrying G551D mutation. It is approved in patients who are six years and older in 150 mg twice daily dosing schedule with fat containing meals. It improves the lung function and other aspects of disease including weight gain. The side effects like upper respiratory infection, headache, rash, diarrhoea, stomach ache and dizziness are mild and self-limiting. This is excellent example of promise of personalised medicine – targeted drug that treat patients with specific genetic makeup. Ivacaftor is First drug that treats an underlying cause of cystic fibrosis to be licensed for use Increases the open probability (i.e. gating) of cystic fibrosis transmembrane conductance regulator channels with the G551D mutation, thus augmenting chloride transport Convenient oral administration Improves lung function and bodyweight parameters when used in combination with standard care in adults, adolescents and children (aged C6 years) with cystic fibrosis and the G551D mutation Generally well tolerated.
Keywords: Ivacaftor, cystic fibrosis, treatment of cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFTR) potentiators, synthesis of ivacaftor
Cite Article: "A Comprehensive Review on Ivacaftor", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.7, Issue 12, page no.383 - 392, December-2022, Available :http://www.ijsdr.org/papers/IJSDR2212057.pdf
Downloads: 000201521
Publication Details: Published Paper ID: IJSDR2212057
Registration ID:202944
Published In: Volume 7 Issue 12, December-2022
DOI (Digital Object Identifier):
Page No: 383 - 392
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631

Click Here to Download This Article

Article Preview

Click here for Article Preview

Major Indexing from www.ijsdr.org
Google Scholar ResearcherID Thomson Reuters Mendeley : reference manager Academia.edu
arXiv.org : cornell university library Research Gate CiteSeerX DOAJ : Directory of Open Access Journals
DRJI Index Copernicus International Scribd DocStoc

Track Paper
Important Links
Conference Proposal
DOI (A digital object identifier)

Providing A digital object identifier by DOI
How to GET DOI and Hard Copy Related
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Creative Commons License
This material is Open Knowledge
This material is Open Data
This material is Open Content
Social Media

Indexing Partner